Back to Trials
NCT07528014Recruiting

ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1

Salma Health, Inc.

Start Date

3/25/2026

Completion Date

3/1/2037

Summary

This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings. The study will examine outcomes among patients treated with interventions including esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). Retrospective clinical and research data from existing databases may also be incorporated, when available and authorized, to support model development and validation. The goal is to assess whether integrated clinical datasets can be used to support the development of predictive tools that may inform personalized treatment selection in depression.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Adults (≥18 years) of any gender identity presenting for care with a depressed mood. * Prescribed treatment with esketamine, conventional TMS, or SAINT as part of standard clinical care. * Able to provide informed consent and comply with all study requirements. Exclusion Criteria: * Any condition deemed by the investigator to preclude safe participation in study assessments.

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Depressed Mood

Locations

Salma Health

La Jolla, California 92037

United States

Salma Health

Laguna Hills, California 92653

United States